REHOVOT, Israel and JERSEY CITY, New Jersey, October 2 /PRNewswire/ --
- The Study Will Compare the Results of Rosetta Genomics' microRNA-based Test, miRview(TM) Squamous, Which Differentiates Squamous From non Squamous non Small Cell Lung Cancer, With Current Diagnostic Methods
- A Test Based on the miRview(TM) Technology First Approved for Clinical use Through Columbia University's High Complexity Molecular Pathology Lab Earlier This Year
- Rosetta Genomics is Expecting to Launch miRview(TM) Squamous Later This Year Through its Recently Acquired CLIA lab in Philadelphia
REHOVOT, Israel and JERSEY CITY, New Jersey, October 2 /PRNewswire/ --